[The pharmacokinetics and pharmacodynamics of pentoxifylline (trental) in the third pregnancy trimester].
As a result of studies into the pharmacokinetics of pentoxyfillin, no significant differences were established in the magnitudes of its non-model parameters in normal pregnancy and chronic placental insufficiency. However, there were differences in the metabolite formation rate in the groups under study. Distinctions were detected in the antiaggregation effect of pentoxyfillin. They consisted in a slower recovery of platelet aggregation parameters to the initial values in the first group examined. There was no good agreement between the concentrations of pentoxyfillin, its major pharmacologically active metabolite in blood plasma of pregnant women and the antiaggregation effect, which reaffirms the indirect action of this drug on platelets.
Boĭko
S S
SS
Zherdev
V P
VP
Vikhliaeva
E M
EM
Supriaga
O M
OM
D000328:Adult; D002853:Chromatography, Liquid; D002908:Chronic Disease; D005260:Female; D006801:Humans; D010431:Pentoxifylline / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D010927:Placental Insufficiency / Q000097:blood / Q000188:drug therapy; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011247:Pregnancy / Q000097:blood / Q000187:drug effects*; D011263:Pregnancy Trimester, Third; D013607:Tablets; D013997:Time Factors
D010975:Platelet Aggregation Inhibitors; D013607:Tablets; D010431:Pentoxifylline
Farmakokinetika i farmakodinamika pentoksifillina (trentala) v III trimestre beremennosti.